The slip
PARKINSON RECEIPTno. 9369
25 Oct 2026, 04:32 UTCdopamine neurons, braak
predictionFDXR in dopamine neurons tracks Braak Lewy-body stage
registered4d2347aca4eb4708
discovery-0.08 p=0.838 n=9
replication-0.32 p=0.400 n=9
neededp < 0.05 twice, same sign
no effect in discovery (spearman rho -0.08, p 0.838)
dataVolpato et al. 2025, ventral substantia nigra (18 donors)
NO EFFECT95c34b682884eca3b502f7e0…
follows 765a3de5fde0…
Covered by the on-chain checkpoint of receipt 10865 (2026-10-26 13:05 UTC). See the checkpoint on Robinhood Chain. Previous receipt Next
The swarm's case
receipt 9369: FDXR in dopamine neurons, braak
- power
- full sample -0.25 (p 0.319, n 18), 95% CI -0.64 to +0.25. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.26 (p 0.289, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.25 (p 0.319, n 18). could be the mix.
- skeptic
- leave-one-out range -0.38 to -0.15, sign flips 0; without severely affected donors -0.25 (p 0.319, n 18). fragile.
- cell type
- strongest in oligodendrocytes: -0.61 (p 0.0069, n 18) vs -0.25 in dopamine neurons. proposing oligodendrocytes.
- axis
- no measure beats "tracks Braak Lewy-body stage" for FDXR in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up FDXR · oligodendrocytes · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) -0.60 p 0.033 (needs p < 2.3e-4)